13.05.2022
Е. Л. Насонов; Т. В. Коротаева
of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.
01.03.2022
Е. Л. Насонов; Т. В. Коротаева; С. Родолфи; К. Ф. Селми
, and safety during the COVID-19 pandemic.
27.02.2022
Б. С. Белов; А. М. Лила; Е. Л. Насонов
The problem of coronavirus disease 2019 (Coronavirus diseases, COVID-19) two years later still
27.12.2021
А. Б. Борисова; Т. А. Лисицына; Д. Ю. Вельтищев; Е. Л. Насонов
and musculoskeletal diseases (RMD) and medical workers at the beginning of the COVID-19.
Material and methods. 150
26.12.2021
Е. Л. Насонов; Е. Файст
and pharmacotherapy of ASD and coronavirus disease 2019 (COVID-19) are considered.
26.12.2021
Е. Л. Насонов; Б. С. Белов; А. М. Лила; Е. С. Аронова; Г. И. Гриднева; А. В. Кудрявцева; Е. В. Сокол; А. В. Торгашина; И. Б. Виноградова; Д. И. Абдулганиева; А. Ю. Зименко
The materials of the Russian NIIR/ARP-COVID-19 database, which included adult (over 18 years old
10.11.2021
Е. Л. Насонов; Е. Файст
фармакотерапии БСВ и коронавирусной болезни 2019 (COVID-19)
05.09.2021
Е. Л. Насонов; А. С. Авдеева
infections, an increase in the risk of a severe course of COVID-19 (coronavirus disease 2019), a decrease
03.08.2021
Е. Л. Насонов; А. С. Авдеева
infections, an increase in the risk of a severe course of COVID-19 (coronavirus disease 2019), a decrease
13.07.2021
Е. Л. Насонов; А. М. Лила; В. И. Мазуров; Б. С. Белов; А. Е. Каратеев; Т. В. Дубинина; О. А. Никитинская; А. А. Баранов; Д. И. Абдулганиева; С. В. Моисеев; А. И. Загребнева
the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world
